Holen Sie sich die Stockscreener-App
67.07
1.79%
-1.22
Schlusskurs vom Vortag:
$68.29
Offen:
$67.495
24-Stunden-Volumen:
1.10M
Relative Volume:
0.39
Marktkapitalisierung:
$6.10B
Einnahmen:
$170.10M
Nettoeinkommen (Verlust:
$-239.59M
KGV:
-23.95
EPS:
-2.8
Netto-Cashflow:
$-191.20M
1W Leistung:
-5.03%
1M Leistung:
+19.21%
6M Leistung:
+72.82%
1J Leistung:
+40.24%
1-Tages-Spanne:
$64.80
$67.50
1-Wochen-Bereich:
$64.80
$78.48
52-Wochen-Spanne:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Vergleichen Sie CRSP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
67.03 | 6.65B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.51 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
473.30 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.47 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.42 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
321.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | JP Morgan | Overweight |
| 2025-02-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Hochstufung | TD Cowen | Sell → Hold |
| 2025-02-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Eingeleitet | Mizuho | Buy |
| 2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-10 | Bestätigt | Needham | Buy |
| 2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-07-28 | Bestätigt | Needham | Buy |
| 2020-07-14 | Eingeleitet | SunTrust | Buy |
| 2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Eingeleitet | Jefferies | Buy |
| 2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-10 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
Is CRISPR Therapeutics AG stock cheap compared to fundamentalsIPO Watch & Fast Moving Market Watchlists - newser.com
Will CRISPR Therapeutics AG continue its uptrendMarket Performance Recap & Real-Time Stock Price Movement Reports - newser.com
Crispr Therapeutics: This Cheap Stock to Buy Is Up 65% in 2025 - Morningstar Canada
Crispr: Investors Waiting Patiently For In-Vivo - Seeking Alpha
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 6.1%Here's Why - MarketBeat
Analyzing net buyer seller activity in CRISPR Therapeutics AGJuly 2025 Pullbacks & Weekly High Potential Stock Alerts - newser.com
Visualizing CRISPR Therapeutics AG stock with heatmaps2025 Price Targets & Weekly High Momentum Picks - newser.com
Visual analytics tools that track CRISPR Therapeutics AG performanceMarket Sentiment Summary & Daily Price Action Insights - newser.com
Crispr Therapeutics price target raised to $75 from $65 at Wells Fargo - TipRanks
Crispr Therapeutics AG: Promising Advancements in Gene Editing and Strategic Market Entry Justify Buy Rating - TipRanks
Citizens reiterates Market Outperform rating on CRISPR Therapeutics stock - Investing.com
CRISPR Therapeutics (CRSP) Is Up 7.9% After Unveiling CTX460 Gene Editing Data for AAT Deficiency Therapy – Has The Bull Case Changed? - Sahm
CRISPR Therapeutics AG stock retracement – recovery analysisMarket Sentiment Review & Long-Term Capital Growth Strategies - newser.com
Measuring CRISPR Therapeutics AG’s beta against major indicesJuly 2025 Levels & Real-Time Stock Entry Alerts - newser.com
Can Owais Metal and Mineral Processing Limited Compete Against Disruptor Stocks in Its SectorStraddle and Strangle Trades & Free Stay Ahead With Picks - earlytimes.in
CRISPR Therapeutics' (CRSP) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
4,245 Shares in CRISPR Therapeutics AG $CRSP Bought by Valeo Financial Advisors LLC - MarketBeat
Crispr Therapeutics AG: Buy Rating Backed by Innovative SyNTase Platform and Promising Preclinical Data - TipRanks
CRISPR Therapeutics AG Hits New 52-Week High of $78.47 - Markets Mojo
CRISPR Therapeutics (CRSP): Valuation Perspective Following Breakthrough SyNTase Preclinical Data and Pipeline Progress - Sahm
CRSP: Needham Reiterates Buy Rating with $81 Target Price | CRSP Stock News - GuruFocus
Crispr Therapeutics AG: Promising Advancements in Gene Editing Justify Buy Rating - TipRanks
CRISPR Therapeutics (NASDAQ:CRSP) Reaches New 12-Month HighShould You Buy? - MarketBeat
CRSP Showcases Promising Preclinical Data for AATD Treatment - GuruFocus
CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform - The Manila Times
CRISPR Therapeutics Highlights Potential Best-in-Class AATD Treatment with CTX460 at ESGCT 2025 Annual Congress - Quiver Quantitative
CRISPR Therapeutics Presents New Preclinical Data for - GlobeNewswire
>90% mRNA correction: CRISPR Therapeutics' CTX460 raises serum AAT >5-fold and shows durable in vivo editing - Stock Titan
Combining machine learning predictions for CRISPR Therapeutics AG2025 EndofYear Setup & Community Consensus Stock Picks - newser.com
McElhenny Sheffield Capital Management LLC Invests $6.62 Million in CRISPR Therapeutics AG $CRSP - MarketBeat
Multi factor analysis applied to CRISPR Therapeutics AG2025 Key Highlights & High Return Stock Watch Alerts - newser.com
CRISPR Therapeutics (NASDAQ:CRSP) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - ADVFN
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
CRISPR Therapeutics Hits Day High with 8.72% Surge in Stock Price - Markets Mojo
CRISPR Therapeutics AG Hits New 52-Week High of $73.95 - Markets Mojo
Tempus AI and CRISPR Therapeutics: The Twin Engines of Precision Medicine - Tokenist
Published on: 2025-10-09 06:29:21 - newser.com
Is CRISPR Therapeutics AG trending in predictive chart models2025 Major Catalysts & Real-Time Price Movement Reports - newser.com
CRISPR Therapeutics Surges 42% as FDA Approval Sparks Fresh Valuation Debate - Yahoo Finance
CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains? - Nasdaq
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 9.5%Time to Buy? - MarketBeat
CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside - ts2.tech
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead - The Globe and Mail
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead - The Motley Fool
Tyche Wealth Partners LLC Increases Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - Yahoo Finance
Slow Capital Inc. Purchases 10,152 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Capital Advisors Inc. OK Sells 300,506 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG stock outlook for YEARWeekly Market Outlook & Free Weekly Watchlist of Top Performers - newser.com
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.02%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):